drugset / Trial / NCT01644253
Phase 1b Safety and Efficacy Study of TRU-016
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.
Timeline
- Start
- 2012-09
- Primary completion
- 2020-02-24
- Completion
- 2021-04-21
Outcome
Outcome not reported
Stopped (Business): “Business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | — | — |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Otlertuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Otlertuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Background | Bendamustine | Small molecule | 90 mg/m2 | — |
| Background | Ibrutinib | Small molecule | — | — |